Apr 18,2023

Teladoc Health Launches Provider-Based Care for Weight Management & Prediabetes Programs

Teladoc Health announced the expansion of Provider-Based Care for weight management and prediabetes programs, besides the currently available programs for diabetes and hypertension. Provider-Based Care delivers an integrated care experience for members, including access to a Teladoc Health physician for a personalized care plan, along with coaching for day-to-day guidance with actionable digital tools. These Teladoc Health solutions are designed to help members lose weight as well as prevent and manage diabetes by safely optimizing medications, such as Glucagon-like peptide (GLP-1) agonists and Sodium-glucose cotransporter-2 (SGLT2) inhibitors, and work in conjunction with the range of Teladoc Health solutions and tools that address the foundational pillars impacting cardiometabolic health. Provider-Based Care became available for diabetes and hypertension solutions nationwide in early 2023. The expansion of this service to weight management and prediabetes will be available in Q3 2023.

PRODUCT

#virtual care

#telehealth

#coaching

View Analyst & Ambassador Comments
Go to original news
Apr 17,2023

ABBOTT'S FREESTYLE LIBRE® CONTINUOUS GLUCOSE MONITORING SYSTEMS OBTAIN SIGNIFICANTLY EXPANDED COVERAGE FOR MEDICARE BENEFICIARIES

The Medicare program has expanded access to continuous glucose monitoring systems like the FreeStyle Libre 2 system and the FreeStyle Libre 14 day system for insulin-using Medicare beneficiaries with diabetes, removing the prior requirement of multiple daily insulin injections. More Medicare beneficiaries than ever before who are living with diabetes and use insulin will now be eligible for reimbursement when using Abbott's FreeStyle Libre® portfolio. The U.S Food and Drug Administration (FDA) just cleared a reader for the FreeStyle Libre 3 system. With the FDA's clearance of a standalone reader, Abbott is working to get the FreeStyle Libre 3 system added to Medicare's list of covered systems as soon as possible.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 17,2023

Dexcom Commends Decision to Expand CGM Medicare Coverage to Include People With Diabetes Using All Types of Insulin

Medicare patients using all types of insulin now have coverage for Dexcom G7– giving approximately 1.5 million more Americans access. The updated Medicare policy is the biggest single expansion of CGM coverage in the U.S. to date. Results from the 2021 MOBILE study, sponsored by Dexcom and using Dexcom CGM, served as the primary piece of clinical evidence that led to this coverage expansion by demonstrating that CGM use significantly improves A1C and increases time in range for adults with Type 2 diabetes on basal insulin.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 17,2023

Tandem Diabetes Care Announces Control-IQ Technology Meta-analysis Demonstrating Positive Clinical Impact of Automatic Correction Bolusing on Glucose Control in People with Type 1 Diabetes

Tandem Diabetes Care announced publication by Diabetes Technology & Therapeutics of a meta-analysis of three randomized controlled trials of its Control-IQ advanced hybrid closed-loop technology. The analysis showed an average increase in time in range of 2.8 hours and a reduction in hemoglobin A1c compared to control groups in people ages 2 to 72 years old. People with the highest baseline blood sugar levels experienced the greatest benefit from the auto-bolus feature of the Control-IQ algorithm. Improvements in time in range for subjects using Control-IQ technology (n=256) were immediate, sustained, and observed across the spectrum of patient characteristics including age, race-ethnicity, parental education, family income, baseline glycated hemoglobin level, virtual vs. in-person training format, and pre-study insulin delivery method. The majority of the control group (n=113) used an insulin pump (91%), some with predictive low glucose suspend technology.

CLINICAL STUDY

#closed loop

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 14,2023

Abbott breaks ground on FreeStyle Libre manufacturing plant in Ireland

Abbott (NYSE:ABT) today broke ground on a new FreeStyle Libre manufacturing facility in Kilkenny, Ireland. Jared Watkin, SVP for Abbott’s diabetes care business, shared the news of the groundbreaking in a LinkedIn post. In August 2022, Ireland announced Abbott’s plans to spend €440 million ($450 million) to expand its operations in Ireland.

View Analyst & Ambassador Comments
Go to original news
Apr 14,2023

FDA CLEARS READER FOR ABBOTT'S FREESTYLE LIBRE® 3 SYSTEM

Abbott today announced that the U.S. FDA has cleared a reader for its FreeStyle Libre® 3 integrated continuous glucose monitoring (iCGM) system. With the FDA's clearance of a standalone reader, Abbott is working to get the FreeStyle Libre 3 system added to Medicare's list of covered systems as soon as possible.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 13,2023

Glytec Unveils the Next Evolution of GlucoMetrics®, Giving Hospital Leaders New Insights and Analytics to Improve Glycemic Management and Readiness for New CMS Measures

Glytec today announced the next evolution of GlucoMetrics® to provide new analytics, dashboards, and data visualizations that give hospitals and health systems new insight into glycemic outcomes. The enhanced visibility comes as hospitals prepare for new measures from the Centers for Medicare and Medicaid Services (CMS) on severe hypoglycemia and hyperglycemia that encourage facilities to report metrics starting in early 2024. GlucoMetrics is powered by data from Glytec’s eGlycemic Management System® (eGMS). Centered on Glucommander,® eGMS is an EHR-integrated, HITRUST certified, cloud-based software system that supports personalized insulin dosing decision support at the point of care. With significant enhancements to GlucoMetrics, glycemic management committees and hospital leaders now have self-serve access to key performance indicators, trends, and benchmarks related to glycemia treatment across their entire health system.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
Apr 12,2023

ViCentra to Participate at the upcoming MedTech Strategist Innovation Summit and LSX London Conference

ViCentra B.V., the company behind Kaleido, one of the world’s smallest, lightest and most precise Insulin Pump systems for treating people with Diabetes, today announced that management will present a corporate overview at the following conferences in April and May: MedTech Strategist Innovation Summit, Dublin, Ireland and LSX World Congress, London, UK.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 11,2023

Tandem Diabetes Care to Announce First Quarter 2023 Financial Results on May 3, 2023

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2023 results after the financial markets close on Wednesday, May 3, 2023. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2023 financial and operating results.

View Analyst & Ambassador Comments
Go to original news
Apr 11,2023

Glooko Announces Partnership with Insulin Dosing Algorithm Company Hedia

Glooko, Inc., announced today a new Global partnership with Hedia, integrating its technology into Glooko's diabetes management platforms for healthcare providers and people with diabetes. With the Glooko platforms, patients currently have the ability to share their diabetes data with their healthcare providers (HCPs), including blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure and weight. With the integration of Hedia Diabetes Assistant, people with diabetes will be able to receive bolus insulin dosing advice, which will provide personalized care and reduce the burden of manually calculating required insulin doses. In addition, when used in conjunction with connected insulin pens, the integrated solution facilitates a high level of visibility for HCPs who are managing patients on multiple daily injection (MDI) therapy. The initial European launch of the integration is expected in the fourth quarter of 2023 and first quarter of 2024.

COLLABORATION PARTNERSHIP

#connected device

#dtx

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES